Yaopharma Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 1, 2027The maintenance fee for Type polypeptide targeting tumours (US 10,428,114) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Podophyllotoxin derivative with 4-position nitrogen substitution and preparation method and application thereof (US 10,639,295) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,639,295 | Podophyllotoxin derivative with 4-position nitrogen substitution and preparation method and application thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,428,114 | Type polypeptide targeting tumours In force · From the USPTO record | In force | From the USPTO record | |
| US 11,161,817 | Quinoline derivative and use thereof as tyrosine kinase inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,149,005 | Organic amine ester derivative drug of 2-(α-hydroxypentyl)benzoic acid In force · From the USPTO record | In force | From the USPTO record | |
| US 12,643,861 | Crystalline Form of Fluvatinib or Fluvatinib Methanesulfonate and Preparation Method Therefor In force · High confidence | In force | High confidence | |
| US 12,419,874 | GLP-1R Agonist Compound and Use Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 1 no status recorded